Recent Updates
Recently added Catalysts
NBIX Positive Sentiment

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results

Key Takeaway: Neurocrine Biosciences has announced a conference call and webcast for its third quarter 2026 financial results, scheduled for November 2, 2026. The press release will precede the call, providing financial insights to investors. The company continues to focus on developing treatments for various neurological and psychiatric disorders, showcasing its commitment to patient care.

Market Sentiment Analysis

POSITIVE FACTORS

  • Scheduled conference call indicates transparency and engagement with investors.
  • Company showcases a commitment to addressing neurological and psychiatric disorders.
  • Diverse portfolio with FDA-approved treatments highlights successful development efforts.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+37%
120-day peak, hindsight
Typical move
3%
average across 5 past catalysts
Lead asset
NBI-1065845
Phase 3 · Major Depressive Disorder

Full Press Release Details

Conference Call and Webcast Scheduled for Monday, November 2

SAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on November 2, 2026.
The schedule for the press release and conference call / webcast is as follows:
• Q3 2026 Press Release: November 2, 2026 at 1:00 p.m. PT / 4:00 p.m. ET
• Q3 2026 Conference Call: November 2, 2026 at 1:30 p.m. PT / 4:30 p.m. ET
• Domestic Dial-In Number: 800-347-6865
• International Dial-In Number: 203-518-9757
• Conference ID: NBIX
The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)
NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

Frequently Asked Questions

When is the Neurocrine Q3 2026 conference call?

The conference call is scheduled for November 2, 2026, at 1:30 p.m. PT.

How can I access the Neurocrine webcast?

The webcast can be accessed on Neurocrine's website under the Investors section.

What will be discussed in the Q3 2026 call?

The call will cover Neurocrine's financial results for the third quarter of 2026.

Is there a replay available for the conference call?

Yes, a replay will be available on the website approximately one hour after the event.

Last updated: Oct 12, 2026